This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Chronic myelogenous leukemia (CML)	IL-1 receptor-like 1 (IL1RL1; ST2); IL-33 (NF-HEV)	<p>Mouse and cell culture studies suggest inhibiting IL-33 signaling could help treat Gleevec imatinib-resistant CML. CD34⁺ cells from patients with CML had surface expression of ST2 and greater proliferation in response to IL-33 than CD34⁺ cells from healthy subjects. IL-33 is an activating ligand for ST2. In patient-isolated CD34⁺ cells, IL-33 blocked the effect of Gleevec on proliferation. Next steps could include evaluating IL-33 inhibitors in combination with Gleevec in models of Gleevec-resistant CML. Novartis AG markets Gleevec, a BCR-ABL tyrosine kinase inhibitor, to treat CML, acute lymphoblastic leukemia (ALL) and gastrointestinal stromal tumors (GISTs).</p> <p>AnaptysBio Inc.'s ANB020, an anti-IL-33 antibody, is in discovery for various inflammatory conditions.</p> <p>SciBX 7(17); doi:10.1038/scibx.2014.488 Published online May 1, 2014</p>	Patent and licensing status unavailable	<p>Levescot, A. <i>et al. Cancer Res.</i>; published online March 27, 2014; doi:10.1158/0008-5472.CAN-13-2797</p> <p>Contact: Andre Herbelin, Institut National de la Santé et de la Recherche Médicale (INSERM), Poitiers, France e-mail: andre.herbelin@inserm.fr</p>